stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Shares outstanding
Vir Biotechnology, Inc.'s shares outstanding at the end of fiscal 2025 was $138.5M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $169.3M. Over the past ten years it has ranged from $2.2M (fiscal 2017) to $138.5M (fiscal 2025) — the current reading is the highest in ten years. Vir Biotechnology, Inc. ranks 69th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $138.5M | 1.67% |
| FY2024 | $136.2M | 1.58% |
| FY2023 | $134.1M | (0.50%) |
| FY2022 | $134.8M | 1.03% |
| FY2021 | $133.4M | 11.98% |
| FY2020 | $119.2M | 292.62% |
| FY2019 | $30.3M | 295.90% |
| FY2018 | $7.7M | 256.23% |
| FY2017 | $2.2M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $169.3M | 0.23% |
| Jun 2026 | $168.9M | 14.61% |
| Mar 2026 | $147.4M | 6.38% |
| Dec 2025 | $138.5M | (0.30%) |
| 28 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| VIR Vir Biotechnology, Inc. | $169.3M |
| BHVN Biohaven Ltd. compare | $151.0M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| IMNM Immunome, Inc. compare | $113.6M |
| REPL Replimune Group, Inc. compare | $105.2M |
| ZYME Zymeworks Inc. compare | $76.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $35.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement